BioXcel Therapeutics, Inc. Repayments of Long-Term Debt
BioXcel Therapeutics, Inc. (BTAI) reported Repayments of Long-Term Debt of $8.41 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2026-08-13
- BioXcel Therapeutics, Inc. repayments of long-term debt for the quarter ending 2026-06-30 was $304.00K.
- BioXcel Therapeutics, Inc. repayments of long-term debt for the quarter ending 2026-03-31 was $8.11M.
- BioXcel Therapeutics, Inc. repayments of long-term debt for the quarter ending 2025-06-30 was $0.00.
- BioXcel Therapeutics, Inc. repayments of long-term debt for the quarter ending 2025-03-31 was $0.00.
- BioXcel Therapeutics, Inc. repayments of long-term debt for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- BioXcel Therapeutics, Inc. repayments of long-term debt for fiscal 2024 was $2.50M.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 12 month |
|---|---|---|---|
| 2026-06-30 | $304.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $8.41M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $8.11M 10-Q · filed 2026-05-15 | ||
| 2025-12-31 | $0.00 10-K · filed 2026-03-27 | ||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-15 | ||
| 2024-12-31 | $2.50M 10-K · filed 2026-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |